WELCOME to this Patient Advocacy organization's informational archive provided by MS Views and News

· Our live MS educational seminars average 72 people per educational program. SINCE our first program in February 2010, we have hosted more than 150 educational programs.

· Visit our Multiple Sclerosis Learning channel on YouTube archived by topic here: www.youtube.com/msviewsandnews

* Be Empowered with beneficial Multiple Sclerosis (MS) information - See our listings of upcoming Educational Programs --

Visit MS Views and News.org

joomla ecommerce template

View all the resources found on the left side of this blog. Use our 'search by topic' tool, when wanting to find specific information



Wednesday, November 14, 2012

Nuron closing in on new treatment for relapsing MS

Tuesday, November 13, 2012
Nuron Biotech Inc. said Tuesday it has completed enrollment of 500 patients for a pivotal phase-III study evaluating the safety and effectiveness of the company’s experimental multiple sclerosis treatment.
Phase-III studies are typically the last hurdle a drug developer must clear before seeking approval for a new drug candidate.
Nuron, an Exton, Pa., specialty biologics and vaccines company, is developing NU100 to treat relapsing remitting multiple sclerosis.
Shankar Musunuri, the company’s founder and CEO, said it expects to complete the study in late 2013.
The company hopes to use the results of the study to support the filing of a European marketing authorization application.
Source: BizJournals


If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left
 REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register

No comments: